Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

0(0%)

Results Posted

100%(6 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_2

43%

Ph phase_1

57%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

4(57.1%)

Phase 2Efficacy & side effects

3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Terminated(1)

Detailed Status

Completed6

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (57.1%)

Phase 23 (42.9%)

Trials by Status

terminated114%

completed686%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_2

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

NCT01059643

completedphase_2

Clinical Trials (7)

Showing 7 of 7 trials

NCT01059643Phase 2

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Completed

NCT01416389Phase 2

A Study of LY2523355 in Participants With Breast Cancer

Completed

NCT01025284Phase 2

A Study for Participants With Small-Cell Lung Cancer

Completed

NCT01214655Phase 1

A Study for Patients With Acute Leukemia

Terminated

NCT01214642Phase 1

A Dose-Escalation Study for Patients With Advanced Cancer

Completed

NCT01214629Phase 1

A Study for Participants With Advanced Cancer

Completed

NCT01358019Phase 1

A Study of LY2523355 in Patients With Solid Cancer

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7